When Virtual Assistants Meet Teledermatology: Validation of a Virtual Assistant to Improve the Quality of Life of Psoriatic Patients.
chat-based interaction
chronic patient support
eHeath
health information technology
mHealth
monitoring virtual assistant
psoriasis
quality of life
remote consultation
teledermatology
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
05 11 2022
05 11 2022
Historique:
received:
20
09
2022
revised:
30
10
2022
accepted:
31
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Teledermatology has given dermatologists a tool to track patients' responses to therapy using images. Virtual assistants, the programs that interact with users through text or voice messages, could be used in teledermatology to enhance the interaction of the tool with the patients and healthcare professionals and the overall impact of the medication and quality of life of patients. As such, this work aimed to investigate the effectiveness of using a virtual assistant for teledermatology and its impact on the quality of life. We conducted surveys with the participants and measured the usability of the system with the System Usability Scale (SUS). A total of 34 participants (30 patients diagnosed with moderate-severe psoriasis and 4 healthcare professionals) were included in the study. The measurement of the improvement of quality of life was done by analyzing Psoriasis Quality of Life (PSOLIFE) and Dermatology Life Quality Index (DLQI) questionnaires. The results showed that, on average, the quality of life improved (from 63.8 to 64.8 for PSOLIFE (with a
Identifiants
pubmed: 36361408
pii: ijerph192114527
doi: 10.3390/ijerph192114527
pmc: PMC9655501
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Med Inform. 2020 Aug;140:104171
pubmed: 32446158
Digit Health. 2019 Aug 21;5:2055207619871808
pubmed: 31467682
Int J Cardiol Hypertens. 2020 Dec;7:100051
pubmed: 33330846
Health Qual Life Outcomes. 2012 May 24;10:56
pubmed: 22624984
Cochrane Database Syst Rev. 2012 Dec 12;12:CD007459
pubmed: 23235644
Psoriasis (Auckl). 2022 Mar 16;12:15-24
pubmed: 35320971
Br J Dermatol. 2008 Nov;159(5):997-1035
pubmed: 18795920
Arch Dermatol Res. 2021 Jan;313(1):11-15
pubmed: 33074356
Br J Dermatol. 2018 Nov;179(5):1062-1071
pubmed: 29654699
JMIR Hum Factors. 2020 Dec 16;7(4):e21161
pubmed: 33325828
JMIR Mhealth Uhealth. 2019 Apr 11;7(4):e11500
pubmed: 30973342
Telemed J E Health. 2017 Sep;23(9):726-732
pubmed: 28570163
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
Dermatol Online J. 2021 Jun 15;27(6):
pubmed: 34387051
BMJ Open. 2020 Jan 30;10(1):e032045
pubmed: 32005778
JMIR Mhealth Uhealth. 2021 Oct 25;9(10):e28149
pubmed: 34431478
Int J Environ Res Public Health. 2021 Nov 17;18(22):
pubmed: 34831811
Health Qual Life Outcomes. 2004 Feb 26;2:12
pubmed: 14987333
J Biomed Inform. 2020 Feb;102:103305
pubmed: 31622802
Cogn Process. 2009 Aug;10(3):193-7
pubmed: 19565283
J Med Internet Res. 2022 Oct 4;24(10):e39063
pubmed: 36179132
JAMA Netw Open. 2018 Oct 5;1(6):e183062
pubmed: 30646223
Am J Prev Med. 2014 Jul;47(1):37-45
pubmed: 24746373
Front Public Health. 2022 Feb 22;10:844669
pubmed: 35273944
J Invest Dermatol. 2019 May;139(5):1037-1044
pubmed: 30481495
Patient Prefer Adherence. 2014 Jan 07;8:63-72
pubmed: 24470755
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
pubmed: 15083780
J Am Acad Dermatol. 2004 Nov;51(5):704-8
pubmed: 15523347